US weight-loss biotech company Kailera has completed a $600 million financing round led by Bain Capital.

On October 14 local time, US weight-loss biotech company Kailera Therapeutics announced the completion of a $600 million Series B financing to further advance the R&D of next-generation obesity treatment drugs. This round of financing was led by new investor Bain Capital, with participation from the Canada Pension Plan Investment Board, the Qatar Investment Authority, etc. (Jiemian)